Moderna Stock Hits New High as CEO Pitches Beyond COVID — SkimNews
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Moderna CEO argued in a WSJ interview that the company's innovation extends well past its COVID vaccines, according to Barron's coverage of the same remarks
- Moderna (NASDAQ:MRNA) stock reached a new high and is on track to rank as September's No. 2 performer in the S&P 500, per Barron's
- Moderna drew Benzinga's after-hours stock-trends coverage alongside Merck (NYSE:MRK), indicating the broader pharma sector is circling the move
- The WSJ framing of a "realistic" approach to innovation — rather than a hype-laden one — sets a deliberately measured tone against the celebratory stock coverage elsewhere
Why it matters: Moderna has been priced almost entirely as a COVID-vaccine company since the pandemic, so the CEO's explicit "more than Covid vaccines" message is the first deliberate attempt to reframe the stock's identity; with MRNA on track for a top-two September finish in the S&P 500, the market is visibly repricing that thesis in real time.
Ask SkimNews
